4 stories mentioning BIOAUpdated 38d ago
Every FINWIRES story that references BIOA, newest first.
Shane Barton, Principal Accounting Officer, on June 29, 2026, sold 62,566 shares in Bioage Labs (BIOA) for $1,576,752.SEC Filing:https://www.sec.gov/Archives/edgar/data/1709941/000183629726000005/xslF345X05/form4-07012026_080701.xml
BioAge Labs (BIOA) has an average rating of buy and mean price target of $49.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
BioAge Labs (BIOA) has an average rating of overweight and mean price target of $51.43, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
BioAge Labs (BIOA) said Tuesday its experimental BGE-102 drug demonstrated "best-in-class reductions" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.Shares of the company rose 9% in Tuesday's premarket activity.Price: $20.49, Change: $+1.69, Percent Change: +8.99%
